Anticoagulation Bridging: Assessment of thrombotic vs. bleeding risk. The modern standard (BRIDGE trial) favors holding therapy without heparin coverage for most patients.
1. Primary Condition
2. Risk Granularity
Consensus Strategy
Thrombotic Risk
Low Risk
The risk of major bleeding from bridging outperforms the thrombotic benefit. Hold VKA as per surgery type.
Verified
Last Review: 2026-07-17
| Risk Class | AF (CHA₂DS₂-VASc) | VTE History | Mechanical Valve |
|---|---|---|---|
| High (Bridge) | ≥ 7 or recent Stroke | VTE < 3 months ago | Any Mitral Valve |
| Moderate | 5 - 6 | VTE 3 - 12 months ago | Aortic (bileaflet) + risk factor |
| Low (No Bridge) | 0 - 4 | VTE > 12 months ago | Aortic (bileaflet) |
Douketis JD et al. • NEJM. 2015;373(9):823-33.
View SourceDouketis JD et al. • Chest. 2022;Support for "No Bridging" in low-to-moderate AF.
View SourceLast Comprehensive Review: 2026-07-17
Scanning Medical Journals
No new significant updates or guidelines matching this topic were found today. We will check again soon.
